<?xml version="1.0"?>
<?xml-stylesheet type="text/xsl" href="billres.xsl"?>
<!DOCTYPE bill PUBLIC "-//US Congress//DTDs/bill.dtd//EN" "bill.dtd">
<bill bill-stage="Introduced-in-House" dms-id="H309749FA77EE49BB9F091EB3FC69BB76" public-private="public" key="H" bill-type="olc"><metadata xmlns:dc="http://purl.org/dc/elements/1.1/">
<dublinCore>
<dc:title>118 HR 8570 IH: Safe In-Home Drug Disposal Initiative Act of 2024</dc:title>
<dc:publisher>U.S. House of Representatives</dc:publisher>
<dc:date>2024-05-24</dc:date>
<dc:format>text/xml</dc:format>
<dc:language>EN</dc:language>
<dc:rights>Pursuant to Title 17 Section 105 of the United States Code, this file is not subject to copyright protection and is in the public domain.</dc:rights>
</dublinCore>
</metadata>
<form>
<distribution-code display="yes">I</distribution-code><congress display="yes">118th CONGRESS</congress><session display="yes">2d Session</session><legis-num display="yes">H. R. 8570</legis-num><current-chamber>IN THE HOUSE OF REPRESENTATIVES</current-chamber><action display="yes"><action-date date="20240524">May 24, 2024</action-date><action-desc><sponsor name-id="H001067">Mr. Hudson</sponsor> introduced the following bill; which was referred to the <committee-name committee-id="HIF00">Committee on Energy and Commerce</committee-name></action-desc></action><legis-type>A BILL</legis-type><official-title display="yes">To establish a pharmacy program to award grants for safe in-home drug disposal and practical medication safety education, and for other purposes.</official-title></form><legis-body id="HB5B258E0EA43401BB1BEC5D4BE5DAE4D" style="OLC"><section id="H190207CF16F3452FAE83352C2E491103" section-type="section-one"><enum>1.</enum><header>Short title</header><text display-inline="no-display-inline">This Act may be cited as the <quote><short-title>Safe In-Home Drug Disposal Initiative Act of 2024</short-title></quote> or the <quote><short-title>SIDDI Act of 2024</short-title></quote>.</text></section><section id="H57962F0D5C7A4489A8ACDFD2948CE62B"><enum>2.</enum><header>Safe in-home drug disposal initiative</header><subsection id="HE2F4C56F6AAD42E481141930E1958138"><enum>(a)</enum><header>In general</header><text display-inline="yes-display-inline">Not later than 180 days after the date of enactment of this Act, the Secretary of Health and Human Services, acting through the Assistant Secretary for Mental Health and Substance Use, (in this section referred to as the <quote>Secretary</quote>) shall establish a program to award grants to States to implement targeted State demonstration initiatives (in this section referred to as <quote>TSDIs</quote>). Such TSDIs shall reimburse licensed pharmacies that choose to participate in the TSDI (in this section referred to as <quote>participating pharmacies</quote>) for the provision to eligible patients, in coordination with the delivery of drug prescriptions, of in-home drug disposal systems and standard medication safety education.</text></subsection><subsection id="H0CE66F14D98A484783C0747AED1BE5F8"><enum>(b)</enum><header>Application</header><text>To be eligible to receive a grant under this section, a State shall submit to the Secretary an application at such time, in such manner, and containing such information as the Secretary may require. Such an application shall—</text><paragraph id="H9E704D24B7F34B89B340E678E1D3008E"><enum>(1)</enum><text>identify the State agency that oversees pharmaceutical care and will be responsible for administering a TSDI through a grant under this section;</text></paragraph><paragraph id="H9DA3C5BF762D49848C270BE07F933BA9"><enum>(2)</enum><text>identify the single pharmacy benefit manager (commonly known as a <quote>PBM</quote>) that will be responsible for—</text><subparagraph id="H86D2E38C0DFE434F9B175619C46EECAC"><enum>(A)</enum><text>adjudicating claims under the TSDI;</text></subparagraph><subparagraph id="HEE0B403B0A7542B88497769724FFBA9B"><enum>(B)</enum><text>reimbursing participating pharmacies; and</text></subparagraph><subparagraph id="HE1D63526092D48ADA01A0428CF85A655"><enum>(C)</enum><text display-inline="yes-display-inline">facilitating the type of customization required to successfully administer a custom, fully transparent program, with pass-through claims adjudication services benefitting patients, plans, and pharmacies;</text></subparagraph></paragraph><paragraph id="H749C04A35C7547B7823C6802ED79392F"><enum>(3)</enum><text>outline the process by which participating pharmacies will submit usual and customary costs related to the reimbursement and remuneration of services, including detailed reporting on—</text><subparagraph id="HC565AE5AC4554B4EBD9D7A621CE4BDE8"><enum>(A)</enum><text>criteria of patient selection;</text></subparagraph><subparagraph id="HB23EE5C423074A9BB738FA9950302F02"><enum>(B)</enum><text>initial activity; and</text></subparagraph><subparagraph id="HFE2A005558074341ADE5D763835ABFC4"><enum>(C)</enum><text>patient engagement factors;</text></subparagraph></paragraph><paragraph id="HF4055438CA52484BAE995A9E7167E0E2"><enum>(4)</enum><text>detail the process through which standard medication safety education will be communicated by each participating pharmacist or pharmacy technician at the point of dispensing, allowing for unique needs and education to be tailored for State-, county-, town-, and municipality-specific needs;</text></paragraph><paragraph id="HED7C8774ADB64F74B7BD7A5231FB94B1"><enum>(5)</enum><text>detail a plan to increase participation rates of pharmacists and pharmacy technicians through a single electronic pharmacy claim process;</text></paragraph><paragraph id="H60E82D8BACE14F1486341DD6B5D6D2EA"><enum>(6)</enum><text>state the remuneration amounts for the provision of standard medication safety education, and the reimbursement amounts for in-home drug disposal systems, which for each eligible patient shall be assessed separately but processed through a single electronic claim;</text></paragraph><paragraph id="HF43985E831354C3BA3257FCE8EC0C420"><enum>(7)</enum><text>describe how the State will select pharmacies to be served under the TSDI; and</text></paragraph><paragraph id="H4558FE58853E475984F91E0BCA1692E0"><enum>(8)</enum><text>include the number of eligible patients to be served under the TSDI.</text></paragraph></subsection><subsection id="H78A9DFCBC033411FBBCA5852B13B99B6"><enum>(c)</enum><header>Number</header><text display-inline="yes-display-inline">The Secretary shall award grants under this section to not more than 5 States.</text></subsection><subsection id="H0A5F3F293E804CE8853D99EFE8691D58"><enum>(d)</enum><header>Grant period</header><text>A grant awarded under this section shall be for a period of at least 3 years.</text></subsection><subsection id="H97BEEE4578FF4739A365B793D21B0CEC"><enum>(e)</enum><header>Accountability and oversight</header><text>As a condition of receiving a grant under this section, a State shall agree to submit to the Secretary, at such time and in such manner as the Secretary may reasonably require, a report on the TSDI of the State implemented through such grant. Such report shall—</text><paragraph id="H8FB8283B08A24B52A6B6DD18087675C8"><enum>(1)</enum><text>list the number of pharmacy locations that are reimbursed through the grant funds;</text></paragraph><paragraph id="H72AE173385CA40E4BA5B6914DECE9813"><enum>(2)</enum><text>describe the activities undertaken by the State using the grant amounts, outlining the in-home drug disposal solutions distributed and the patient education delivered;</text></paragraph><paragraph id="H59FFCF9C1AFF4E60939484B6EE72C386"><enum>(3)</enum><text>survey pharmacies to collect demographic information on participating patients, medication types prescribed, and the effective use of the in-home drug disposal systems; and</text></paragraph><paragraph id="HA92EFA85060E40C9A5D0B7B667BBC8A0"><enum>(4)</enum><text>contain performance measures relating to the effectiveness of the grant, including changes in the participation rate of eligible patients and the engagement with pharmacists.</text></paragraph></subsection><subsection id="H3E82E364D02946558D764B8150CA0212"><enum>(f)</enum><header>Definitions</header><text> In this section:</text><paragraph id="H4D65120C0ABC4E3DA80D2CB4458E2218"><enum>(1)</enum><header>Eligible patients</header><text>The term <term>eligible patients</term> means patients receiving an opioid prescription who are at risk of experiencing an opioid-related overdose, including such patients—</text><subparagraph id="H12A1A8A562B54D2DB628AD209A2D1C60"><enum>(A)</enum><text>with a first-time opioid prescription;</text></subparagraph><subparagraph id="H49FBB10B7D8749BFAD03021269346A63"><enum>(B)</enum><text>with an acute opioid prescription prescribed for a short-term illness or condition; or</text></subparagraph><subparagraph id="H344C57D96255415E995645C8FA95A2A4"><enum>(C)</enum><text display-inline="yes-display-inline">that have received a change in the opioid dosage of an acute or chronic opioid prescription. </text></subparagraph></paragraph><paragraph id="H0B42630794E84A9E9BCB55DA92AD9974" commented="no"><enum>(2)</enum><header>In-home drug disposal system</header><text> The term <term>in-home drug disposal system</term> means a system of drug disposal—</text><subparagraph id="H6DB6F88C9311461E9F21905B77F2FEC4" commented="no"><enum>(A)</enum><text>that changes the physical integrity of the formulation of a drug;</text></subparagraph><subparagraph id="H04D0BF32D1CE475697DB0FB33F676B82" commented="no"><enum>(B)</enum><text>that renders the active ingredients of such drug unusable for all practical purposes;</text></subparagraph><subparagraph id="H769B4CA4BF0344F99E3AD8A5A93F56E2" commented="no"><enum>(C)</enum><text>that—</text><clause id="HD646109355EF490680445A233F53C57D" commented="no"><enum>(i)</enum><text>is nontoxic and nonhazardous;</text></clause><clause id="H489949C9461A42539ACA7FACDDD36B96" commented="no"><enum>(ii)</enum><text>poses no threat to the consumer; and</text></clause><clause id="HFEC7A3CB82A144DFBDC33077EE564875" commented="no"><enum>(iii)</enum><text>reduces drug exposure to the environment; and</text></clause></subparagraph><subparagraph id="H1B82956DCFC24AEC99E9D37F3B60E241" commented="no"><enum>(D)</enum><text>that acts as a deterrent for misuse of drugs.</text></subparagraph></paragraph><paragraph id="H1664602D451A4D85B41545480CCEC913" commented="no"><enum>(3)</enum><header>Standard medication safety education</header><text>The term <term>standard medication safety education</term> means medication safety education—</text><subparagraph id="H0D15D7B39846440C93EEB8BA213E6948" commented="no"><enum>(A)</enum><text display-inline="yes-display-inline">provided by a pharmacist or pharmacy technician to eligible patients for a duration of not more than 5 minutes per patient; and</text></subparagraph><subparagraph id="H4E590A353D3643A9A2C5A1230D1F24A8" commented="no"><enum>(B)</enum><text>that includes information relating to—</text><clause id="H6A88F078B3664E2C9CD97D7EB83482E0" commented="no"><enum>(i)</enum><text>proper medication storage;</text></clause><clause id="H27FA42DA3BAA407197695B6FA19681A3" commented="no"><enum>(ii)</enum><text>risks associated with keeping unused medication in the home;</text></clause><clause id="HB14EE86A79EB489A8075BB7CC5E3F712" commented="no"><enum>(iii)</enum><text>proper in-home disposal of unused medication; and</text></clause><clause id="H2531D3FEF5204AE29ABAB89F9628A447" commented="no"><enum>(iv)</enum><text>in the case of naloxone that is prescribed as an opioid medication, the proper use of such naloxone</text></clause></subparagraph></paragraph><paragraph id="H58D2267948C242A98E24E4177CB22F26"><enum>(4)</enum><header>State</header><text>The term <term>State</term> means each of the several States, the District of Columbia, and any territory of the United States.</text></paragraph></subsection><subsection id="H094AE95F2C6745DF95FC3E3C53F58BCE"><enum>(g)</enum><header>Authorization of appropriations</header><text>There is authorized to be appropriated to carry out this section $56,000,000 for the period of fiscal years 2025 through 2029.</text></subsection></section></legis-body></bill> 

